News|Articles|August 3, 2026

5 Endocrinology Headlines You Missed in July 2026

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

July 2026 was relatively quiet for endocrinology. The US Food and Drug Administration (FDA) had no significant approvals, instead accepting 2 exciting New Drug Applications (NDAs) for the treatment of hypocalcemia and acromegaly, respectively. Additionally, key trials for type 1 diabetes (T1D), type 2 diabetes (T2D), and weight maintenance following GLP-1 RA discontinuation had topline results read out over the course of the month, moving major candidates like encaleret and tegoprubart further down the treatment pipeline towards an FDA decision.

Related to this article

September 17th, 2026

FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes

The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.

September 15th, 2026

Diabetes Dialogue: Beta Bionics' Mint Patch Pump Gains FDA Clearance

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.

Image Credit: US Food and Drug Administration

September 14th, 2026

FDA Clears Beta Bionics' Mint Insulin Patch Pump for Diabetes

Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.

September 15th, 2026

FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis

FDA accepts Cogent's bezuclastinib NDA for advanced systemic mastocytosis, backed by APEX trial data showing durable, high-rate responses.

September 14th, 2026

Ameluz Treatment Becomes First FDA-Approved PDT for Skin Cancer

Ameluz is now the first FDA-approved photodynamic therapy for a skin cancer, expanding use to superficial basal cell carcinoma (sBCC) in adults.

September 14th, 2026

FDA Priority Review Granted to Zasocitinib for Moderate to Severe Psoriasis

Phase 3 data show zasocitinib use led to clear or almost clear skin in around 70% of patients by Week 16, setting up an FDA decision in early 2027.

September 10th, 2026

Diabetes Dialogue: Tirzepatide's New CV Indication and the STAREE Statin Trial

Diana Isaacs, PharmD, and Natalie Bellini, DNP, unpack tirzepatide's new CV indication and the STAREE statin trial in older adults.

September 17th, 2026

Q&A: What the First FDA-Approved PDT for Skin Cancer Means for sBCC Care

Neal Bhatia, MD, weighs the newly approved Ameluz PDT regimen for sBCC against Mohs surgery, citing its 66% composite response rate.